New criteria make high-risk smoldering multiple myeloma treatable, opening door to future 'chronic' disease status ...

The EMA has extended the indications for Darzalex (daratumumab) to the treatment of adults at high risk of developing multiple myeloma.

Multiple myeloma bone lesions occur when cancerous cells cause the bones to form weak spots, which can lead to breaks. Learn more about lesions and pain.

Fatigue, bone pain, and frequent infections can all be signs of the blood cancer multiple myeloma, which often has no early distinctive symptoms.

For patients newly diagnosed with multiple myeloma, optimal outcomes start with a clear set of goals. "The primary goals of initial treatment are straightforward: relieve symptoms like anemia ...

NICE leads the way in approving breakthrough treatment for multiple myeloma People in England will become the first in the world to receive belantamab mafodotin for this indication following our ...

Could Johnson & Johnson’s Trispecific Antibody Redefine Treatment for Relapsed or Refractory Multiple Myeloma? “The response rate with JNJ-5322 is encouraging as we explore the potential of this ...

Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...

The future of multiple myeloma treatment is personalised, but collaboration is essential to deliver it. Learn about the latest advancements and how working together can improve outcomes for patients.

Sanofi earns CHMP backing to expand Sarclisa's use for newly diagnosed multiple myeloma patients eligible for transplant.

Sundar Jagannath, MBBS, highlights long-term follow-up data from the phase 1b/2 CARTITUDE-1 trial, showing durable responses and potential cures with ciltacabtagene autoleucel in patients with ...